By meeting its primary endpoint, this trial demonstrated for the first time the feasibility and safety of neoadjuvant radioimmunotherapy prior to radical cystectomy in patients with locally advanced bladder cancer, warranting further investigation in a randomized setting.
Schmid et al. (Sun,) studied this question.